Continuum Advisory’s CONMED CNMD Stock Holding History

Continuum Advisory’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11	Closed	-$753	–	1725
2024 Q4	$753	Hold	11	–	–	﹤0.01%	1668
2024 Q3	$783	Hold	11	–	–	﹤0.01%	1687
2024 Q2	$763	Hold	11	–	–	﹤0.01%	1524
2024 Q1	$774	Buy	+11	New	+$980	﹤0.01%	1515

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Continuum Advisory's CNMD Position: Q1 2025 in Review

Continuum Advisory sold out of CONMED (CNMD) in Q1 2025, closing a stake of 11 shares — an estimated $753 sold.

Continuum Advisory first reported a position in CNMD in Q1 2024 and held it in 4 quarters. The position peaked at $783 in Q3 2024. 280 funds tracked by Wall St. Rank hold CNMD as of Q1 2025.

Continuum Advisory reported no remaining CONMED position as of Q1 2025 after selling out during the quarter.
Continuum Advisory sold 11 CONMED shares in Q1 2025, an estimated $753.
Continuum Advisory first reported a position in CONMED in Q1 2024 and held it in 4 quarters.
Continuum Advisory's CONMED position peaked at $783 in Q3 2024.
280 funds tracked by Wall St. Rank held CONMED as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.